Advertisement
Frost & Sullivan's team of industry analysts conducted over 400 hours ofanalysis in the diagnostics market. "During the process of conducting theresearch, it became clear that AdvanDx would be a strong candidate to receivethe in-vitro molecular diagnostic technology innovation of the year award,"said Abhishek Dutta, Research Analyst, Frost & Sullivan. "PNA FISH is anextremely innovative technology platform that prevents the unnecessary use ofdrugs, enables doctors to make rapid diagnoses, treat patients sooner, savelives and significantly reduce costs throughout all areas of the hospital. Asa result, AdvanDx is diversifying into new product lines that will enable thefirm to explore new, multi-billion dollar in-vitro diagnostic markets," Duttaadded.
Advertisement
"This Award further validates the impact of AdvanDx's molecular diagnosticproducts in the marketplace," said Thais T. Johansen, President and CEO ofAdvanDx. "We appreciate that Frost & Sullivan has formally recognized thefundamental breakthrough value of our technology platform to provideclinicians with critical information as early as possible to help guidepatient care, improve outcomes, and reduce hospital length-of-stay and costs.There are many diagnostic products, so it was particularly noteworthy thatAdvanDx has been singled out for recognition," Johansen concluded.
Research Methodology and Selection Process Criteria
To choose The Technology Innovation of the Year Award recipient, Frost &Sullivan's analyst team conducted a selection process that included primaryinterviews and extensive primary and secondary research via a bottom-upapproach. The analyst team considered AdvanDx's pace of research andtechnology innovation and its significance and relevance to the overallindustry. The ultimate Award recipient was selected after a thoroughevaluation of this research.
About Frost & Sullivan
Frost & Sullivan, the Growth Consulting Company, partners with clients toaccelerate their growth. The company's Growth Partnership Services, GrowthConsulting and Career Best Practices empower clients to create a growth-focused culture that generates, evaluates and implements effective growthstrategies. Frost & Sullivan employs over 45 years of experience in partneringwith Global 1000 companies, emerging businesses and the investment communityfrom more than 30 offices on six continents. For more information, visithttp://www.frost.com.
About AdvanDx
AdvanDx is the world's leading provider of fast, accurate and easy-to-usein vitro molecular diagnostic products that advance the prevention, diagnosisand treatment of infectious pathogens. AdvanDx's products and services enabledramatic improvements in patient care and outcomes while reducing hospitalcosts.
Every year, 350,000 patients contract bloodstream infections, causing over90,000 unnecessary deaths and significant costs to the healthcare system. Therapid identification of infecting pathogens is crucial to ensure early andappropriate therapy to save lives and reduce patient length-of-stay. Inresponse, AdvanDx leverages its molecular diagnostic products to detect andidentify infectious pathogens and provide therapy-directing results in hoursversus days.
AdvanDx's easy-to-use products employ standard lab techniques andequipment
